Corxel Pharmaceuticals completed a $287 million Series D to advance CX‑11, an oral GLP‑1 receptor agonist licensed from Vincentage, through planned global Phase II and preparatory Phase III work. The financing will support U.S. phase II enrollment for obesity, a planned global phase II in type 2 diabetes, and initial phase III preparations, the company said. Management framed the round as funding to accelerate global development and commercialization planning for a potential oral alternative to injected GLP‑1 therapies.